<DOC>
	<DOCNO>NCT01896921</DOCNO>
	<brief_summary>This clinical study propose evaluate combination maraviroc integrase strand transfer inhibitor ( either raltegravir dolutegravir ) antiretroviral-experienced patient document efficacy , safety , tolerability combination order provide clinician treatment regimen minimize risk metabolic complication avoidance NRTI/NNRTIs PIs . The development alternative ART regimen lessen risk metabolic complication could improve long-term adherence reduce risk certain co-morbidities associate long-term ART use . If new combination find efficacious standard regimen enhance tolerability improve metabolic effect , great potential altering current practice HIV medicine .</brief_summary>
	<brief_title>Switch Maraviroc + Integrase Inhibitor</brief_title>
	<detailed_description>Description study design : The study enroll 30 HIV-infected patient stable ART regimen suppress HIV RNA &lt; 50 copies/ml least one year . Patients switch experimental regimen ( maraviroc 300 mg twice day plus either raltegravir 400 mg twice day dolutegravir 50 mg a-day ) follow 96 week . The decision use raltegravir dolutegravir leave investigator/subject preference , two integrate inhibitor largely interchangeable aside twice daily ( raltegravir ) vs. daily ( dolutegravir ) dosing . Primary endpoint : - The primary endpoint proportion patient virologically suppress ( HIV RNA &lt; 50 copies/ml ) 48 week . Definitions : - Virologic suppression HIV RNA &lt; 50 copies/ml . - Virologic failure HIV RNA ≥ 50 copies/ml confirm 2 separate occasion , separate &gt; 1 week viral suppression . Secondary endpoint : - The percent change total cholesterol , LDL , HDL 48 96 week . - The number adverse event . - The proportion patient virologically suppress ( HIV RNA &lt; 50 copies/ml ) 96 week . Exploratory endpoint : - Telomerase activity telomere length measure baseline 24 , 48 , 96 week .</detailed_description>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>HIV1 infection Age 18 75 year CD4 count nadir ≥ 250 cells/mm3 HIV RNA ≤ 50 copies/ml ≥ 12 month take ART regimen One virologic blip ≤ 400 copies/ml permissible within 12 month CCR5 tropic virus define : trofile/tropism test available , OR DNA trofile trofile/tropism test available CD4 nadir 250499 cells/mm3 , OR CD4 nadir ≥ 500 cells/mm3 Age &lt; 18 &gt; 75 year CD4 count nadir &lt; 250 cells/mm3 Dual/mixed X4 tropic virus test prior viral suppression perform DNA trofile test time Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal Women : currently pregnant breastfeed childbearing age agree remain abstinent use ( partner use ) acceptable method birth control throughout study . Acceptable method birth control define intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , condom , vasectomy . History malignancy except nonmelanoma skin cancer Concomitant use drug know impact impact term pharmacokinetics drugdrug interaction either raltegravir maraviroc . This include : Inducers UGT1A1 ( rifampin , phenytoin , phenobarbital rifabutin , St. John 's wort ) CYP3A inhibitor ( ketoconazole , itraconazole , clarithromycin , nefazodone , telithromycin ) CYP3A inducer ( rifampin , carbamazepine , phenobarbital phenytoin ) Subject require anticipated require prohibit medication note protocol Enrollment experimental protocol receive investigational agent ( antiretroviral nonantiretroviral ) within 30 day study enrollment Chronic active hepatitis B infection define presence HBsAg Subject history current evidence condition , therapy , laboratory abnormality circumstance might interfere patient 's participation full duration study , best interest patient participate . Subject unlikely adhere study procedure , keep appointment , plan relocate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>